Shares of Radius Health, Inc. (NASDAQ:RDUS) have been assigned a consensus recommendation of “Hold” from the eleven research firms that are presently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $56.40.
RDUS has been the subject of a number of recent research reports. Cantor Fitzgerald reaffirmed a “buy” rating and set a $58.00 price target on shares of Radius Health in a research note on Friday. Jefferies Group LLC cut their price target on Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a research note on Friday. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $45.00 price target on shares of Radius Health in a research note on Friday, October 6th. Zacks Investment Research downgraded Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Finally, Maxim Group reaffirmed a “positive” rating on shares of Radius Health in a research note on Friday, September 29th. They noted that the move was a valuation call.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/11/05/radius-health-inc-rdus-receives-consensus-recommendation-of-hold-from-analysts.html.
In related news, CFO Jose Carmona acquired 3,000 shares of the business’s stock in a transaction that occurred on Thursday, September 14th. The shares were acquired at an average cost of $32.83 per share, with a total value of $98,490.00. Following the purchase, the chief financial officer now owns 3,000 shares of the company’s stock, valued at $98,490. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Growth N. V. Biotech acquired 150,000 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was bought at an average cost of $34.97 per share, for a total transaction of $5,245,500.00. Following the completion of the purchase, the insider now directly owns 5,113,799 shares in the company, valued at approximately $178,829,551.03. The disclosure for this purchase can be found here. Insiders purchased a total of 519,100 shares of company stock worth $17,970,882 over the last three months. 15.00% of the stock is owned by company insiders.
Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. grew its holdings in Radius Health by 98,245.6% in the 1st quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock valued at $101,679,000 after buying an additional 2,628,070 shares during the last quarter. Farallon Capital Management LLC grew its holdings in Radius Health by 18.3% in the 2nd quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock valued at $166,731,000 after buying an additional 569,300 shares during the last quarter. TimesSquare Capital Management LLC acquired a new stake in Radius Health in the 2nd quarter valued at approximately $25,589,000. BB Biotech AG grew its holdings in Radius Health by 11.0% in the 2nd quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock valued at $227,905,000 after buying an additional 498,400 shares during the last quarter. Finally, RA Capital Management LLC acquired a new stake in Radius Health in the 2nd quarter valued at approximately $22,486,000.
Shares of Radius Health (NASDAQ RDUS) opened at $29.56 on Friday. Radius Health has a one year low of $27.16 and a one year high of $55.97.
Radius Health (NASDAQ:RDUS) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.03). The company had revenue of $13.50 million during the quarter, compared to analysts’ expectations of $6.90 million. During the same period in the prior year, the company posted ($1.07) earnings per share. research analysts anticipate that Radius Health will post -5.28 EPS for the current fiscal year.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
What are top analysts saying about Radius Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Radius Health Inc. and related companies.